Followers | 36 |
Posts | 2,689 |
Boards Moderated | 0 |
Alias Born | 06/09/2011 |
Twitter Profile: | Temporarily Unavailable |
Follow on Twitter: | Follow @ Temporarily Unavailable |
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Nice move up with buying picking up
The market is getting hammered today with DOW down over 500 points, Nasdaq down 150 points and NWBO is holding steady actually looking to push PPS higher and into green on light volume as of now. VRTX and JUNO both hit 52 week lows today as well as many others!
who just sold 340 shares of HRTPY for $49??? This has been going on for a while with trading volume so low!
Outside, P5 specifically used my posts/tweets in the original P5 article as well as DiamondJim's post/tweets and had us as paid pumpers for NWBO. I responded immediately that this is just absurd and being one of the longest members on this board they had this totally wrong and it was removed from the Seeking Alpha Phase 5. DiamondJim responded to this as well. This P5 report was a total hit piece and I hope I am contacted by Mr. Nathan regarding this BS.
As for messages I posted on oncology boards was to let potential patients and family members know there are other treatment options to investigate with their oncologist. I received many thank you's for passing on information that they could research and discuss with their physician/oncologist.
As for being a paid pumper I am NOT. I an too busy at work with a lot of responsibility and post in early mornings, evenings or weekends when time permits.
Austin, I agree we have not heard one update on HE in Germany and seeing that we are coming up in March on (2) two year anniversary from original PR and 8-9 clinics in Germany they must be getting close to finalizing agreements IMO. We will see I guess.....
Interesting....Russian message board referencing a patient going Dusseldorf,Germany for a cancer vaccine. One of the posts mentions vaccine based approaches for glioblastoma.
https://translate.google.com/translate?hl=en&sl=ru&u=http://tutnetam.com/viewtopic.php%3Ff%3D47%26t%3D127362%26p%3D3663363&prev=search
2016 16th Annual UCLA Brain Tumor Conference
at the UCLA Brain Tumor Center
Save the Date
March 11-12, 2016
Friday, March 11th from 8:00am to 5:00pm
Saturday, March 12th from 8:00am to 2:30pm
UCLA Carnesale Commons
251 Charles E. Young Drive West
Los Angeles, CA 90095
http://www.neurooncology.ucla.edu/SaveTheDate2016BTC.pdf
I just found it interesting we are now approaching 2 years from the HE announcement which my gut instinct is feeling we are very close to HE agreements being finalized especially with all the clinics listed in Germany.
NWBO receiving Hospital Exemption granted from PEI in Germany will be (2) two years as of March 11, 2016. You would think negotiations are done by now???
NW Bio are two German approvals known "hospital exemption" for an early access program with DCVax-L and eligibility for reimbursement for DCVax-L
03/11/2014 - 09:40
Bethesda, Maryland (ots / PRNewswire) - - DCVax-L is the first product of its kind, which the German authorities granted an exception Hospital
Northwest Biotherapeutics (NW Bio), a biotechnology company that develops personally tailored DCVax® immunotherapy for solid tumors, announced today that it from the Paul Ehrlich Institute ("PEI" - the FDA Germany) a permit as a "hospital exception "Early access program known has received pursuant to § 4b of the Medicines Act. According to this hospital exception can NW Bio outside the clinical trials of the company DCVax-L charge for the treatment of all forms of Gliomhirntumoren (both glioblastoma multiforme and gliomas lower grades) administered to patients, both newly diagnosed and recurrent, and for the full price , Patients may come from Germany or other countries. This authorization is valid for five years and can be applied for and issued again with this deadline.
There is a long history between UPenn and NWBO and very good relationship between Dr. Bosch and the (2) leaders of UPenn's medical research group Dr. Carl June and Dr. George Koukos. They have collaborated in abstracts with Dr. Bosch on DC vaccination in ovarian cancer and Cognate was the manufacturer of the vaccine in that UPenn trial.
I can assure you if VP Biden visited UPenn, Dr. June and Dr. Koukos would be involved as they are two of the most respected in the field of oncology, DC vaccination and research.
UPenn is also current clinic in DCVax-L GBM trial as well as the Expanded Access trial!
http://www.stopovariancancer.com/about.shtml
Pfizer looks to cut the line in CAR-T with off-the-shelf approach
January 14, 2016 | By Damian Garde
http://www.fiercebiotech.com/story/pfizer-looks-cut-line-car-t-shelf-approach/2016-01-14?utm_medium=nl&utm_source=internal
Hope we see the buying continue strong today as we have finally pushed into the green and looking to move higher.
Absolutely Smokey! ACAD, CLDX hit 52 week low today, JUNO came within $.03 of 52 week low this morning. Bio's getting hammered
Here is snapshot of how trading today stayed within a range...Nasdaq down 160 points as well
Total Shares Traded PPS Time
113,750 $2.11 10:33
210,297 $2.11 12:24
279,281 $2.11 13:56
341,749 $2.10 14:55
357,052 $2.06 15:15
380,986 $2.09 15:33
430,951 $2.06 15:50
I could not have said that any better and agree with you 100%!
I agree as Ponezumab abstract showing very promising results, add Pfizer Ponezumab trial results are complete or nearly complete and Shire with their Phase I trial for FA shows it to be efficacious, ILNS patent portfolio on Neuro disease has significant value to either company IMHO.
Great point on this issue!
Another great find montanus regarding Ponezumab. Pfizer must have or nearly complete their Phase II data for Ponezumab via ILNS. It would be great to get an trial data PR on this and Shire for their Phase I trial for FA as well.
I noticed there are 9 clinics showing in Germany and I remember the count being 8 as of the last time i looked. I might be wrong but I also get the feeling all this updating is being done for an announcement soon.
Thanks for sharing montanus! Shire still has FA listed in Rare Disease Pipeline which I take as positive as I would think if data from the Phase I was not efficacious, they most likely not have it still listed on their pipeline. GLTA on ILNS!
iwasadiver....always like to read your posts on this board.
What I find encouraging and positive in this recent (Oct 2015) video content the presenter is Dr. Linda Liau, Principal Investigator with Dr. Marnix Bosch of NWBO for the Phase III international trial for DCVax-L.
She is considered one of the best neuro surgeons in world let alone the United States. This video was a great find!
Beach... totally agree on this video presentation by Dr. Liau. Worth watching a second time!
Drilla, as always thanks for sharing this with the board!
Looks like manipulation today with 756 shares traded someone trying to push this lower! We need some substantial news from the company in 2016
One of your better posts Afford with interesting view on recent events with NW and NWBO.
New Peer Reviewed Article Describes Role of TauC3 in AD Transgenic Mice
Marketwired-ILNS
TauC3 Mice Showed Drastic Learning and Spatial Memory Deficits and Reduced Synaptic Density at a Young Age (2-3 months); First Published Study Describing Role of TauC3 in Vivo; Study Independently Conducted by Scientists at School of Biological Sciences, Seoul National University, Seoul, Republic of Korea
http://money.cnn.com/news/newsfeeds/articles/marketwire/11G077919-001.htm
Totally agree Tony as I was just going to post the same message!
PetitionFund more research into brain tumours, the biggest cancer killer of under-40s in UK.
https://petition.parliament.uk/petitions/105560
Unlike most cancers, brain cancer incidence is rising.
• Less than 20% of those diagnosed with brain cancer survive beyond 5 years.
• In 2014, brain tumours received 1.5% (£7.7 million) of the £498 million national spend on research into cancer. At this rate, it could take 100 years to catch up with developments in other diseases.
The charity is calling on the Government and larger cancer charities to raise investment to £30-£35 million a year, and this petition aims to support its campaign.
The National Institute for Health Research (NIHR) welcomes funding applications for research into any aspect of human health, including brain tumours. These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and the NHS, value for money and scientific quality. NIHR funding is not ring-fenced for cancer research or for research on brain tumours or other types of cancer. In all disease areas, the amount of NIHR funding depends on the volume and quality of scientific activity.
The Government welcomes the commitment by Cancer Research UK to increase spend in research on brain tumours. This will drive further investment by the NIHR. This happens in two ways. Firstly, as scientific breakthroughs are translated into interventions benefitting patients through infrastructure for experimental medicine. Secondly, investment is driven as emerging interventions are investigated in studies and trials through the NIHR Clinical Research Network.
Department of Health
Beach, what a great find on Sawston for NWBO and DCVax! This is very much appreciated and just reconfirms significant progress there. I look forward to your future post as well!
GLTA and Happy and Prosperous New Year to NWBO longs in 2016!
It is so impressive and I like the following section in plan.
http://plan.scambs.gov.uk/swiftlg/MediaTemp/1132583-504307.pdf
dok.....very interesting perspective and one that is synergistic to my own evaluation that is currently going on. Left me thinking Hmmmm!
I agree TC especially when you see the data presented by NWBO, the recent IHUB post #48881 by autologous regarding his friend in Expanded Access Trial and is now going 4 years survival with DCVax-L.
The comment on QOL being so important and we have heard this before with DCVax patients reporting this as well.
GLTA in 2016!
Thank you for sharing this with the board You are providing a real life story and your friend's DCVax experience that is very much appreciated by me. GLTA in 2016!
Speculation Austin....just like the post which seemed sincere on that message board as I was reading it.
Very interesting post on Inspire MB on DCVax. Bold and Italics done by me regarding Germany comments.
https://www.inspire.com/groups/american-brain-tumor-association/discussion/not-wonderful-new-about-dcvax/?page=last#replies
Great post and very well articulated in getting your message across. Thanks for sharing.
Jeannine Walston – 17-Year Brain Tumor Thriver
Anti-Cancer Club Information
November 11, 2015 at 1:47 pm • ?2 Comments
I agree with you on his post Flip! Woodford must not be to happy with his own internal team and their vetting process in regards to this whole NWBO situation especially after NWBO management identified conflicts of interest in their interview process and due diligence.
Northwest Biotherapeutics to Probe CEO Allegations
DOW JONES & COMPANY, INC. 12:05 PM ET 12/8/2015
Northwest Biotherapeutics Inc. (NWBO) said Tuesday that it rejected a recommended board seat appointment and established a special committee to investigate recent allegations against Chairman and Chief Executive Linda Powers.
Questions have been raised about financial dealings between Northwest and entities related to Ms. Powers. The CEO has termed the allegations as "baloney," adding that payments had been cleared by the Northwest board, independently audited and filed where necessary with regulators.
Last month, Neil Woodford, a U.K. fund manager well known for investing in the biotech industry, urged Northwest to hold an inquiry into the allegations. He also proposed the board appoint Elliott Leary, a former special agent of the Federal Bureau of Investigation who conducts investigations for the global risk-management firm Freeh Group International Solutions LLC, as a nonexecutive director.
Northwest said Tuesday that it still plans to appoint an independent board director but Mr. Leary wasn't a fit because of his lack of board, biotech and pharmaceutical experience.
The company said it also determined not to retain the Freeh Group, saying the firm isn't fully independent because it has been affiliated with Northwest's competitors.
Instead, Northwest's special committee selected Irvin Nathan and Steven Kaplan of Arnold & Porter LLP, neither of whom the company said has previously done any work for Northwest or is otherwise connected with the company.
Northwest also has engaged Charles Price--a former FBI agent and current board member at MorganFranklin Consulting LLC where he leads the corporate investigations and dispute solutions practice--as a consultant to the board.
"As we announced last week, we welcome Mr. Woodford's recent call for an investigation to address the allegations," said board member Jerry Jasinowski, who is part of the special committee, "and we agree with Mr. Woodford that the investigation needs to be fully independent."
Mr. Woodford's firm, Woodford Investment Management, said in an email statement, "We are pleased the company agrees with our recommendation to appoint a new nonexecutive director and undertake a special investigation of the allegations."
Ms. Powers was unavailable for comment Tuesday but told The Wall Street Journal last month that she welcomed an investigation and "wanted to see this stuff put to rest once and for all."
Northwest said the special committee anticipates the investigation will start in the coming week and take at least 90 days.
Shares of Northwest, down 47% over the past three months, added a penny to $4.21 in midday trading in New York.
Denise Roland contributed to this article.
Write to Anne Steele at Anne.Steele@wsj.com
(END) Dow Jones Newswires 12-08-151205ET Copyright (c) 2015 Dow Jones & Company, Inc.
LMAO reading this post! Welcome to the board Ceolwynn!
Bill, I totally agree with you. Phase 5 report has no listed authors and targeted DJ and me as paid message board posters for NWBO which I find comical.
I am thrilled with this announcement by Woodford and NWBO has already fully supported this move. It is my belief you will see an extensive investigation by Freeh Group and Mr. Leary into the stock manipulation and naked shorting of NWBO. With their FBI history and current connections and tools available to them, I expect we will see some real progress in finding evidence in this specific area.